Instrumento Inactivo

Otros idiomas Protagonist Therapeutics Inc Nasdaq

Acciones

US74366E1029

Precio de cierre Nasdaq Otros sitios de cotización
- ^PTS	-

07/05	Protagonist Therapeutics, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
03/04	Insider de Protagonist Therapeutics vendió acciones por valor de 707.750 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Protagonist Therapeutics: Q1 Earnings Snapshot	07/05
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	03/04
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	27/03
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	26/03
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	18/03
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	11/03
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	11/03
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	04/03
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	04/03
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	04/03
Protagonist Therapeutics: Q4 Earnings Snapshot	27/02
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	01/02
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	31/01
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	30/01
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	15/12
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial	13/12
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	13/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Protagonist Therapeutics Inc Nasdaq

Acciones

US74366E1029

Otros idiomas

Filtros